J
José C. Milisenda
Researcher at University of Barcelona
Publications - 73
Citations - 1287
José C. Milisenda is an academic researcher from University of Barcelona. The author has contributed to research in topics: Myositis & Dermatomyositis. The author has an hindex of 15, co-authored 56 publications receiving 693 citations. Previous affiliations of José C. Milisenda include Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Classification and management of adult inflammatory myopathies.
Albert Selva-O'Callaghan,Iago Pinal-Fernandez,Ernesto Trallero-Araguás,José C. Milisenda,Josep Maria Grau-Junyent,Andrew L. Mammen,Andrew L. Mammen +6 more
TL;DR: Treatment is still largely based on expert opinion, but several studies have shown effectiveness of different therapies in various subsets of inflammatory myopathies, and advances will undoubtedly improve the outcomes of patients with inflammatory myopathy.
Journal ArticleDOI
Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations.
Albert Selva-O'Callaghan,Marcelo Alvarado-Cardenas,Iago Pinal-Fernandez,Ernesto Trallero-Araguás,José C. Milisenda,Maria Angeles Martínez,Ana Marin,Moises Labrador-Horrillo,Cándido Juárez,Josep Maria Grau-Junyent +9 more
TL;DR: Clinical phenotypes including rhabdomyolysis, myalgia and/or mild hyperCKemia, self-limited toxin statin myopathy, and immune-mediated necrotizing myopathy are herein described.
Journal ArticleDOI
Identification of distinctive interferon gene signatures in different types of myositis.
Iago Pinal-Fernandez,Iago Pinal-Fernandez,Iago Pinal-Fernandez,Maria Casal-Dominguez,Maria Casal-Dominguez,Assia Derfoul,Katherine Pak,Paul H. Plotz,Frederick W. Miller,José C. Milisenda,Josep M. Grau-Junyent,Albert Selva-O'Callaghan,Julie Paik,Jemima Albayda,Lisa Christopher-Stine,Thomas E. Lloyd,Andrea M. Corse,Andrew L. Mammen,Andrew L. Mammen +18 more
TL;DR: IFN1 and IFN2 pathways are differentially activated in different forms of myositis, which may have therapeutic implications because immunosuppressive medications may preferentially target each of these pathways.
Journal ArticleDOI
Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis.
Iago Pinal-Fernandez,Iago Pinal-Fernandez,Iago Pinal-Fernandez,Berta Ferrer-Fabregas,Ernesto Trallero-Araguás,Eva Balada,Maria Angeles Martínez,José C. Milisenda,Gloria Aparicio-Español,Moises Labrador-Horrillo,Vicente García-Patos,Vicente García-Patos,Josep M. Grau-Junyent,Albert Selva-O'Callaghan,Albert Selva-O'Callaghan +14 more
TL;DR: Tumours from paraneoplastic anti-TIF1γ-positive patients showed an increased number of genetic alterations, such as mutations and LOH, in TIF1 genes, which may be key to understanding the genesis of paranoplastic myositis.
Journal ArticleDOI
Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies.
Rebecca De Lorenzo,Iago Pinal-Fernandez,Wilson Huang,Jemima Albayda,Eleni Tiniakou,Cheilonda Johnson,José C. Milisenda,Maria Casal-Dominguez,Andrea M. Corse,Sonye K. Danoff,Lisa Christopher-Stine,Julie J. Paik,Andrew L. Mammen +12 more
TL;DR: Unlike patients with DM, AS, or IMNM, anti-PM/Scl-positive patients have weaker arm abductors than hip flexors and have the most extensive extramuscular features.